Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -7.69% |
management commentary, guidance changes, and full analysis available with Pro.
| -7.69% |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter and expressed a commitment to their strategic objectives. They remain focused on overcoming current challenges.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized a focus on long-term goals despite short-term setbacks.
Nektar Therapeutics reported a loss that was slightly worse than expected, leading to a modest decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. The stock's slight drop reflects market uncertainty following the earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FOMENTO ECONOMICO ME ADR
Feb 27, 2017